Document Detail


Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro.
MedLine Citation:
PMID:  8280489     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hexadecylphosphocholine (HePC), an experimental and clinical antitumour agent of the alkyllysophospholipid group, was tested for its radiosensitising effect on a panel of nine human mammary cancer cell lines in vitro. Growth inhibition by ionising radiation and recovery from it were not influenced by pretreatment with HePC in most cases, except for two cell lines expressing an activated ras oncogene. In the latter we found an enhanced radioresistance that was abolished by pretreatment with HePC. Our results suggest that HePC may act as a radiosensitiser for cells carrying an activated ras oncogene.
Authors:
E A Bruyneel; G A Storme; D C Schallier; D L Van den Berge; P Hilgard; M M Mareel
Related Documents :
19954229 - Extracellular remodelling during oncogenic ras-induced epithelial-mesenchymal transitio...
19760159 - Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells wit...
7626109 - Beta 1-6 branching of n-linked carbohydrate is associated with k-ras mutation in human ...
19414339 - Development of targeted therapy with paclitaxel incorporated into egf-conjugated nanopa...
11776079 - C-myc gene inactivation during induction of nasopharyngeal carcinoma cells with retinoi...
16374429 - Distinct functions for ras gtpases in the control of proliferation and apoptosis in mou...
7595189 - Migration of human inflammatory cells into the lung results in the remodeling of arachi...
22530779 - Naphthoquinones from onosma paniculata induce cell-cycle arrest and apoptosis in melano...
25470679 - Apoptosis versus cytotoxicity in hela cells exposed to paracetamol.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  29A     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  1993  
Date Detail:
Created Date:  1994-02-16     Completed Date:  1994-02-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1958-63     Citation Subset:  IM    
Affiliation:
Department of Radiotherapy, University Hospital Ghent, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology*
Breast Neoplasms / genetics*
Cell Survival / drug effects
Female
Gene Expression Regulation, Neoplastic
Genes, ras*
Humans
Phosphorylcholine / analogs & derivatives*,  pharmacology
Radiation Tolerance / drug effects*
Radiation-Sensitizing Agents / pharmacology*
Time Factors
Tumor Cells, Cultured / drug effects
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Radiation-Sensitizing Agents; 107-73-3/Phosphorylcholine; 58066-85-6/miltefosine
Comments/Corrections
Erratum In:
Eur J Cancer 1994;30A(4):571

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry a...
Next Document:  HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection.